# "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

> **NCT03219710** · PHASE3 · COMPLETED · sponsor: **All India Institute of Medical Sciences** · enrollment: 240 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Dexamethasone
- **DRUG:** Aprepitant
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT03219710
- **Lead sponsor:** All India Institute of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219710, ""Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03219710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*